Structure Therapeutics Inc ADR Dossier - Source-backed chat

Structure Therapeutics Inc ADR

GPCRNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.68

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $28.98Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.1B

Enterprise Value $1.8B

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Structure Therapeutics Inc. (GPCR) is a highly promising clinical-stage biopharmaceutical company specializing in oral small-molecule therapeutics for chronic metabolic diseases, primarily obesity. The company's lead asset, aleniglipron (GSBR-1290), has demonstrated best-in-class oral efficacy in its Phase 2 ACCESS II trial, achieving up to 16.3% placebo-adjusted weight loss at 44 weeks with no evidence of a plateau. Backed by a robust cash reserve of $1.5 billion that secures its operational runway through 2028, Structure is well-positioned to initiate its Phase 3 registrational program in Q3 2026. The transition of aleniglipron to Phase 3, combined with a highly experienced leadership team and a pipeline of next-generation oral amylin receptor agonists, presents a compelling high-upside opportunity in the multi-billion dollar metabolic space.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets15 analysts · as of 18 Aug 2026

Low · most bearish analyst$69.50

Mean target$104.77

High · most bullish analyst$145.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$44.00

Phase 3 trials face enrollment delays or unexpected safety signals (e.g., severe GI adverse events or liver toxicity) that increase discontinuation rates. Competitors with oral GLP-1 or combination therapies capture the market first, reducing aleniglipron's commercial viability. The lack of a strategic partner forces the company to heavily dilute shareholders to fund commercialization.

Base CaseCentral scenario

$104.77

Matches the consensus mean

Structure successfully initiates its Phase 3 program for aleniglipron in Q3 2026 with a 2.5 mg starting dose, showing improved GI tolerability. The cash runway remains secure through 2028, and early-stage pipeline assets (ACCG-2671 and ACCG-3535) progress on schedule. The stock moves steadily toward the consensus analyst target as clinical milestones are met.

Bull CaseUpside scenario

$120.00

Aleniglipron's Phase 3 trials demonstrate superior weight loss (>18%) and a highly competitive tolerability profile with low discontinuation rates. The oral amylin program (ACCG-2671) delivers strong Phase 1 results, establishing a powerful combination franchise. Structure secures a lucrative co-development or commercialization partnership with a major pharmaceutical firm, driving the stock toward the high end of analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Best-in-class oral efficacy with aleniglipron achieving up to 16.3% weight loss, comparable to injectable GLP-1 therapies.
Strong balance sheet with $1.5 billion in cash, cash equivalents, and short-term investments, providing a runway through 2028.
Clear regulatory path with positive FDA end-of-Phase 2 feedback and Phase 3 initiation on track for Q3 2026.
Expanding pipeline including oral amylin receptor agonists (ACCG-2671 and ACCG-3535) for potential combination therapies.

Key Investment Risks

Intense competitive pressure from established pharmaceutical giants (e.g., Eli Lilly, Novo Nordisk) and emerging biotech players in the oral GLP-1 space.
Clinical development and regulatory approval risks inherent to Phase 3 trials.
Potential tolerability issues, particularly gastrointestinal adverse events, which are common to the GLP-1 class.

Thesis Invalidation Triggers

Failure to initiate the Phase 3 program for aleniglipron in 2H 2026.
Unexpected severe adverse events or high discontinuation rates in the Phase 3 trials.
A significant reduction in cash runway due to unprojected clinical or operational expenses.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.